Sickle-cell disease surgery

Revision as of 18:36, 24 October 2016 by Anthony Gallo (talk | contribs)
Jump to navigation Jump to search

Sickle-cell disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sickle-cell disease from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Sickle-cell disease surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sickle-cell disease surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

National Guidelines Clearinghouse

NICE Guidance

FDA on Sickle-cell disease surgery

CDC on Sickle-cell disease surgery

Sickle-cell disease surgery in the news

Blogs onSickle-cell disease surgery

Directions to Hospitals Treating Sickle-cell disease

Risk calculators and risk factors for Sickle-cell disease surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2]

Overview

Surgical intervention is generally not recommended for the management of sickle-cell disease. However, certain surgeries may be performed for specific complications.

Surgery

Surgical intervention is generally not recommended for the management of sickle-cell disease. However, elective splenectomy can be performed after the first episode of a splenic sequestration crisis.[1] Cholecystectomy can be done for patients who develop [[cholecystitis\\ or symptoms of gallbladder disease.[1] For patients who develop choledocholithiasis, endoscopic retrograde cholangiopancreatography (ERCP) may be done.

References

  1. 1.0 1.1 Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I; et al. (2012). "Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management". ScientificWorldJournal. 2012: 949535. doi:10.1100/2012/949535. PMC 3415156. PMID 22924029.